COVID-19 drugs, the trial on Remdesivir continues on the International Space Station
The studies on the COVID-19 drugs continue: on the International Space Station research on the remdesivir
For the past 20 years, astronauts have been performing experiments on the International Space Station.
Science in low Earth orbit is not only hugely important in preparation for continued space exploration, the research also benefits life on Earth.
We’ve seen discoveries that have advanced Earth-bound medicine, engineering and agriculture, and from this weekend onwards, microgravity will help us in our fight against COVID-19, with European commercial experiments set to launch to the International Space Station on the 21st SpaceX cargo mission.
Covid-19 drugs: the study on the cyclodextrin of Remdesivir
Scientists will use Europe’s commercial ICE Cubes Service to test a COVID-19 medicine in microgravity in order to better understand how remdesivir interacts with its delivery substance cyclodextrin so that the drug’s efficiency can be improved.
It will be the first time any COVID-19 related research takes place on the International Space Station.
The experiment represents collaboration at its finest: The customers, InnoStudio and Cyclolab, are using the High Quality Protein Crystal Growth Service Kirara, operated by the Japan Manned Space Systems Corporation (JAMSS), to run an experiment in the ICE Cubes Facility, managed by Space Application Systems, in ESA’s Columbus laboratory.